BAUSCH HEALTH AMERICAS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: 3.1K

Market Cap: -

Website: http://www.bauschhealth.com

Clinical Trials

Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis

Phase 4

Not yet recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: High dose budesonide rectal foam
Drug: Low dose budesonide rectal foam
Drug: Matching placebo rectal foam

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 100

Registration Number: NCT05976802

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Phase 3

Active, not recruiting

Conditions: Hepatic Encephalopathy

Interventions: Drug: Placebo
Drug: Rifaximin SSD

First Posted Date: 2022-03-28

Last Posted Date: 2024-05-09

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 466

Registration Number: NCT05297448

Locations: 🇺🇸
Bausch Site 482, Valencia, California, United States
🇺🇸
Bausch Site 452, Miami Lakes, Florida, United States
🇺🇸
Bausch Site 577, Macon, Georgia, United States

and more 184 locations

Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 50 mg/mL Virazole Inhalant Product
Drug: 100 mg/mL Virazole Inhalant Product
Drug: Placebo

First Posted Date: 2022-02-08

Last Posted Date: 2022-02-08

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 32

Registration Number: NCT05229510

Locations: 🇨🇦
Bausch Site 1, Mississauga, Ontario, Canada

Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

Active, not recruiting

Conditions: Psoriasis

Interventions: Biological: Brodalumab
Biological: Matched cohort

First Posted Date: 2021-11-24

Last Posted Date: 2024-10-29

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 394

Registration Number: NCT05132231

Locations: 🇨🇦
CARE Site 52, Saint-Charles-Borromée, Quebec, Canada
🇨🇦
CARE Site 42, Calgary, Alberta, Canada
🇨🇦
CARE Site 26, Calgary, Alberta, Canada

and more 39 locations

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: High Dose Rifaximin ER
Drug: Low Dose Rifaximin ER
Drug: Low Dose Rifaximin DER
Drug: Placebo
Drug: High Dose Rifaximin DER

First Posted Date: 2021-10-28

Last Posted Date: 2023-09-07

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 44

Registration Number: NCT05098028

Locations: 🇺🇸
Bausch Site 105, Orange, California, United States
🇰🇪
Bausch Site 502, Kisumu, Kenya
🇺🇸
Bausch Site 103, Denver, Colorado, United States

and more 5 locations

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Phase 3

Active, not recruiting

Conditions: Hepatic Encephalopathy

Interventions: Drug: Rifaximin SSD
Drug: Placebo

First Posted Date: 2021-10-08

Last Posted Date: 2024-03-22

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 524

Registration Number: NCT05071716

Locations: 🇺🇸
Bausch Site 219, Atlanta, Georgia, United States
🇺🇸
Bausch Site 140, Los Angeles, California, United States
🇺🇸
Bausch Site 189, Los Angeles, California, United States

and more 147 locations

Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment

Not Applicable

Completed

Conditions: Photoaging

Interventions: Device: CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.

First Posted Date: 2021-08-30

Last Posted Date: 2023-11-22

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 28

Registration Number: NCT05027282

Locations: 🇺🇸
Bausch Site 001, Dallas, Texas, United States

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: IDP-126 Gel
Drug: IDP-126 Vehicle Gel
Drug: Epiduo® Forte Gel

First Posted Date: 2021-05-19

Last Posted Date: 2023-09-07

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 686

Registration Number: NCT04892706

Locations: 🇺🇸
Bausch Site 142, High Point, North Carolina, United States
🇺🇸
Bausch Site 110, Fremont, California, United States
🇺🇸
Bausch Site 135, North Miami Beach, Florida, United States

and more 39 locations

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

Phase 2

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: High Dose MT-1303
Drug: Low Dose MT-1303

First Posted Date: 2021-04-23

Last Posted Date: 2023-12-15

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 322

Registration Number: NCT04857112

Locations: 🇺🇸
Salix Site 007, Rialto, California, United States
🇺🇸
Bausch Site 008, Lafayette, Louisiana, United States
🇺🇸
Bausch Site 012, Suffolk, Virginia, United States

and more 19 locations

Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19

Phase 1

Completed

Conditions: COVID19

Interventions: Drug: 50 mg/mL Virazole
Drug: 100 mg/mL Virazole

First Posted Date: 2020-09-16

Last Posted Date: 2021-08-26

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 51

Registration Number: NCT04551768

Locations: 🇬🇷
Bausch Health Site 201, Athens, Attika, Greece
🇬🇷
Bausch Health Site 204, Alexandroupoli, Evros, Greece
🇲🇽
Bausch Site 304, Tijuana, Zona Rio, Mexico

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy